Raphael Veil

Mr. Raphael Veil

Assistance Publique – Hôpitaux de Paris, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKostas Danis
Kostas Danis
OEOlivier Epaulard
Olivier Epaulard
TBThomas Bénet
Thomas Bénet
AGAlexandre Gaymard
Alexandre Gaymard
SCSéphora Campoy
Séphora Campoy
CSChristine Saura
Christine Saura
Background: On 7 February 2020, French Health authorities were informed of a confirmed case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an Englishman infected in Singapore who had recently stayed in a chalet in the French Alps. We conducted an investigation to identify secondary cases and interrupt transmission.Methods: We defined as a confirmed case a person linked to the chalet with a positive reverse-transcription polymerase chain reaction sample for SARS-CoV-2.Results: The index case stayed 4 days in the chalet with 10 English tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in England (including the index case), and 1 in Spain (overall attack rate in the chalet: 75%). One pediatric case, with picornavirus and influenza A coinfection, visited 3 different schools while symptomatic. One case was asymptomatic, with similar viral load as that of a symptomatic case. Seven days after the first cases were diagnosed, 1 tertiary case was detected in a symptomatic patient with from the chalet a positive endotracheal aspirate; all previous and concurrent nasopharyngeal specimens were negative. Additionally, 172 contacts were monitored; all contacts tested for SARS-CoV-2 (N = 73) were negative.Conclusions: The occurrence in this cluster of 1 asymptomatic case with similar viral load as a symptomatic patient suggests transmission potential of asymptomatic individuals. The fact that an infected child did not transmit the disease despite close interactions within schools suggests potential different transmission dynamics in children. Finally, the dissociation between upper and lower respiratory tract results underscores the need for close monitoring of the clinical evolution of suspected cases of coronavirus disease 2019.

1 March 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
MDMichel Dupuis
Michel Dupuis
LDLéo Delbos
Léo Delbos
RVRaphael Veil
Raphael Veil
CACatherine Adamsbaum
Catherine Adamsbaum

16 October 2023 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
MDMichel Dupuis
Michel Dupuis
LDLéo Delbos
Léo Delbos
ARAlexandra Rouquette
Alexandra Rouquette
CACatherine Adamsbaum
Catherine Adamsbaum
RVRaphael Veil
Raphael Veil

3 April 2018 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
ILIvan Lerner
Ivan Lerner
RVRaphael Veil
Raphael Veil
DNDinh-Phong Nguyen
Dinh-Phong Nguyen
VLVinh Phuc Luu
Vinh Phuc Luu
RJRodolphe Jantzen
Rodolphe Jantzen
Revolution in Health Care: How Will Data Science Impact Doctor–Patient Relationships?

6 March 2019 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
SBSimon Bussy
Simon Bussy
RVRaphael Veil
Raphael Veil
VLVincent Looten
Vincent Looten
ABAnita Burgun
Anita Burgun
SGStéphane Gaïffas
Stéphane Gaïffas
AJAnne-Sophie Jannot
Anne-Sophie Jannot
Choosing the most performing method in terms of outcome prediction or variables selection is a recurring problem in prognosis studies, leading to many publications on methods comparison. But some aspects have received little attention. First, most comparison studies treat prediction performance and variable selection aspects separately. Second, methods are either compared within a binary outcome setting (where we want to predict whether the readmission will occur within an arbitrarily chosen delay or not) or within a survival analysis setting (where the outcomes are directly the censored times), but not both. In this paper, we propose a comparison methodology to weight up those different settings both in terms of prediction and variables selection, while incorporating advanced machine learning strategies. Using a high-dimensional case study on a sickle-cell disease (SCD) cohort, we compare 8 statistical methods. In the binary outcome setting, we consider logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosting (GB) and neural network (NN); while on the survival analysis setting, we consider the Cox Proportional Hazards (PH), the CURE and the C-mix models. We also propose a method using Gaussian Processes to extract meaningfull structured covariates from longitudinal data. Among all assessed statistical methods, the survival analysis ones obtain the best results. In particular the C-mix model yields the better performances in both the two considered settings (AUC =0.94 in the binary outcome setting), as well as interesting interpretation aspects. There is some consistency in selected covariates across methods within a setting, but not much across the two settings. It appears that learning withing the survival analysis setting first (so using all the temporal information), and then going back to a binary prediction using the survival estimates gives significantly better prediction performances than the ones obtained by models trained “directly” within the binary outcome setting.

15 March 2020 in AIDS
Verified
Journal Article
Closed access
RVRaphael Veil
Raphael Veil
IPIsabelle Poizot-Martin
Isabelle Poizot-Martin
JRJacques Reynes
Jacques Reynes
CGCecile Goujard
Cecile Goujard
RSRemonie Seng
Remonie Seng
LMLaurence Meyer
Laurence Meyer
Current international guidelines recommend either boosted protease inhibitor (PI/r)–based or integrase inhibitors (INSTI)–based regimens during primary HIV infection (PHI), even though the latter have only demonstrated their superiority at the chronic stage. We compared the effectiveness of INSTI- versus PI/r-based combined antiretroviral therapy (cART) initiated during PHI. This study was conducted among patients who initiated cART between 2013 and 2017, using data from the ANRS-PRIMO cohort and the Dat’AIDS study. Cumulative proportions of patients reaching viral suppression (HIV-1 RNA <50 cp/mL) were calculated using Turnbull's estimator for interval-censored data. CD4 cells and CD4/CD8 ratio increases were estimated using mixed linear models. Results were adjusted for the data source. Among the 712 study patients, 299 received an INSTI-based cART. Patients baseline characteristics were similar between groups. Viral suppression was reached more rapidly in INSTI- versus PI/r-treated patients (p < 0.01), with cumulative proportions of 37% vs 6% at 4 weeks, 77% vs 38% at 12 weeks, 92% vs 79% at 24 weeks and 93% in both groups at 48 weeks. At 4 weeks, INSTI-treated patients had gained on average 40 CD4 cells/μl (p=0.05) over PI/r-treated ones; mean CD4 counts were similar in the two groups at 48 weeks. The CD4/CD8 ratio followed the same pattern. Results were similar when restricted to a comparison between Dolutegravir- vs Darunavir-based cART. Based on this study and available literature, we recommend the use of INSTI-based cART for treatment initiation during PHI, since it leads to faster viral suppression and immune restoration.